• Home

  • Documents

  • EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry -...
12
1

EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

  • Upload
    leque

  • View
    213

  • Download
    0

Embed Size (px)

Citation preview

Page 1: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

1

Page 2: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

2

Page 3: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

3

Page 4: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

4

Page 5: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

5

Page 6: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

6

Page 7: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

7

Page 8: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

8

Page 9: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

CORE 11/30/2017 4:43 PMCORE 11/30/2017 4:43 PM11/30/2017 4:43 PMAbbott template 2 11/30/2017 4:43 PM

Page 10: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

10

Page 11: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

11

Page 12: EBE conference 05 Dec 2017 - Case study tisagenlecleucel · A case study from industry - tisagenlecleucel (CTL019) Miriam Fuchs, PhD Global Drug Development, Regulatory Affairs EBE

12


Sesion1 Logica Ebe

Sesion1 Logica Ebe

Education
Redarquía ebe jc

Redarquía ebe jc

Business
Ebe Eduardo Evia

Ebe Eduardo Evia

Documents
CTL019 CRS Supplement v04.04.16 · We collected laboratory and clinical data from patients treated on 3 clinical trials designed to assess the safety and feasibility of CTL019 T cell

CTL019 CRS Supplement v04.04.16 · We collected laboratory and clinical data from patients treated on 3 clinical trials designed to assess the safety and feasibility of CTL019 T cell

Documents
รายงานภาพกิจกรรม EBE & EIS ... · PDF fileรายงานภาพกิจกรรม EBE & EIS International Conference นางเบญจลักษณ์

รายงานภาพกิจกรรม EBE & EIS ... · PDF fileรายงานภาพกิจกรรม EBE & EIS International Conference นางเบญจลักษณ์

Documents
Novartis CTL019 – JULIET data on DLBCL · • JULIET is a global clinical trial with centralized manufacturing of CTL019 • 27 sites in 10 countries across North America, Europe,

Novartis CTL019 – JULIET data on DLBCL · • JULIET is a global clinical trial with centralized manufacturing of CTL019 • 27 sites in 10 countries across North America, Europe,

Documents
Ebe Randeree @ eranderee

Ebe Randeree @ eranderee

Documents
2018 EBE IN DEALERSHIP DIGITAL NETWORK · PDF file2018 ebe in dealership digital network facility image requirements & standards december 2017 version 1.1 contents ebe in dealership

2018 EBE IN DEALERSHIP DIGITAL NETWORK · PDF file2018 ebe in dealership digital network facility image requirements & standards december 2017 version 1.1 contents ebe in dealership

Documents
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse … · Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report 5 Table 14:

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse … · Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report 5 Table 14:

Documents
Unidad iii ebe

Unidad iii ebe

Health & Medicine
tipos de EBE`s

tipos de EBE`s

Documents
Ebe u2 act5_politica_economica_en_el_proceso_de_integracion

Ebe u2 act5_politica_economica_en_el_proceso_de_integracion

Education
CTL019 (tisagenlecleucel) - U S Food and Drug ... (tisagenlecleucel) is a genetically modified autologous immunocellular therapy indicated for the treatment of pediatric and young

CTL019 (tisagenlecleucel) - U S Food and Drug ... (tisagenlecleucel) is a genetically modified autologous immunocellular therapy indicated for the treatment of pediatric and young

Documents
Pesquisa Tipologia EBE

Pesquisa Tipologia EBE

Documents
Tisagenlecleucel for the treatment of relapsed or

Tisagenlecleucel for the treatment of relapsed or

Documents
Trabajo EBE

Trabajo EBE

Health & Medicine
EBE Porte Catalog

EBE Porte Catalog

Documents
Divisibilidad Ebe Sesion4

Divisibilidad Ebe Sesion4

Education
EBE Mech Eng

EBE Mech Eng

Documents
EBE 2009 Dossier Prensa

EBE 2009 Dossier Prensa

Technology
EBE SILVIO GALVIS

EBE SILVIO GALVIS

Documents
EBE - Conceptos y Procedimientos

EBE - Conceptos y Procedimientos

Documents
Ade Kai Eni Ebe

Ade Kai Eni Ebe

Documents
EbE Vertexing for Mixing

EbE Vertexing for Mixing

Documents
Tisagenlecleucel infusion in patients with relapsed ...allEM eta unoter Cancer 2219e1225 doi11136itc221225 1 Open access Tisagenlecleucel infusion in patients with relapsed/refractory

Tisagenlecleucel infusion in patients with relapsed ...allEM eta unoter Cancer 2219e1225 doi11136itc221225 1 Open access Tisagenlecleucel infusion in patients with relapsed/refractory

Documents
Boletín EBE-UI

Boletín EBE-UI

Documents
Considerations in Setting Specifications - EBE€¦ · BE-1050 Brussels info@ebe-biopharma.org EBE ... will have specifications and the storage time will be supported by ... Perspectives

Considerations in Setting Specifications - EBE€¦ · BE-1050 Brussels [email protected] EBE ... will have specifications and the storage time will be supported by ... Perspectives

Documents
20 Adherencia Salamanca EBE Definitivo

20 Adherencia Salamanca EBE Definitivo

Documents
Ebe 2010 analitica web

Ebe 2010 analitica web

Technology
8 ebe]o9bWii8 ebe]o9bWii - WordPress.com · 8 ebe]o9bWii8 ebe]o9bWii - WordPress.com ... ƒ⁄žÛ)

8 ebe]o9bWii8 ebe]o9bWii - WordPress.com · 8 ebe]o9bWii8 ebe]o9bWii - WordPress.com ... ƒ⁄žÛ)

Documents